Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic ...
Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.
Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...
Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...
A study led by TUM researchers finds that cystic fibrosis alters immune cells early in life, likely before birth. These ...
Limb-girdle muscular dystrophy type 2D (LGMD2D/R3) is a rare genetic disorder caused by mutations in the SGCA gene, leading to defective folding and the loss of functional α-sarcoglycan, with ...
Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers ...
As someone who does not benefit from any CFTR modulators, I only have one option for improving my lung function — transplant. But just because it’s my only choice does not mean it’s an easy one to ...
Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...
The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback